A1C for pre-diabetic range
5.7-6.4%
Species of tick implicated in Lyme disease
Ixodid
Most common cause of LGIB
Hemorrhoids
Age to start breast cancer screening in average risk women
40 years
Valsartan - Sacubtril
Class and dose of drug indicated for individual with DM 40-75 years of age
Mod dose statin
CD4 count cut off for starting PJP prophylaxis
< 200
Gastrointestinal hamartomas associated with a number of cancers, such as breast, thyroid, kidney, and colon cancer
Cowden syndrome
this is the grade of recommendation for screening of pancreatic cancer in asymptomatic individuals
D
Drug implicated with highest risk of C diff
Clindamycin
Metformin is contraindicated below this eGFR
< 30
As per IDSA this test is not required to determine start of antimicrobial therapy in CAP
Procalcitonin
3 reasons for referral of an individual to a Liver Tx Center
- Cirrhosis with MELD > 15
- Decompensated Cirrhosis
- ALF
Age upto which USPTF recommends continuing lung cancer screening
upto 80 years
Starts at 55 years
Metabolic disturbance that could be seen with use of Carbamazepine
hyponatremia
Assymetric weakness and pain in lower limbs because of pathology in LS plexus
Diabetic amyotrophy
treatment of choice with this dimorphic fungi

Itraconazole
Testing for dyspepsia symptoms in individuals < 60 years of age
Non invasive H pylori testing
Screening recommended for all individuals above 18 years of age
BP or unhealthy alcohol use
Accept any
thrombopoietin receptor agonists used for refractory ITP
eltrombopag (given orally daily) and romiplostim (given subcutaneously weekly)
Blood test besides CGM/SBGM which can be used for inconsistent A1C
Fructosamine or 1,5-anhydroglucitol (1,5-AG)
Glycated Albumin
Accept any
Newest FQ approved that is active against MRSA
Delafloxacin
Treatment of microscopic colitis if conservative measures fail
Oral Budesonide
As per CDC, the use of this vaccine now includes shared decision making
PCV 13
Drug class used in treatment of osteoporosis in individuals with CKD or intolerant of 1st line therapy
RANK B ligand inhibitors
DO NOT ACCEPT DENOSUMAB